Table 2:

A comparison of blood immune cell populations at pre-ETI treatment (baseline) between Control patients without CF (N=5) and pwCF (N=15) and a comparison of blood immune cell populations in pwCF Pre-ETI treatment (baseline) and 3-months Post-ETI treatment.

	Controls n=5	pwCF n=15	Controls vs. pwCF at Baseline1		pwCF n=15	pwCF Pre-ETI (at baseline) vs. 3 months Post-ETI2
	At baseline	At baseline (Pre-ETI)			Post-ETI
	Mean ±SD		Mean difference±SD	p	Mean ±SD	Mean difference±SD	p
Neutrophils	47.3 ±6	73.0 ±7.1	−25.7 ±17.1	0.001*	56.6 ±16.7	−16.4 ±17.4	0.003*
Eosinophils	2.7 ±1.7	1.5 ±1.2	1.2 ±3.2	0.091	4.4 ±2.2	3 ±2.4	<0.001*
CD3+	30 ±6.5	13.5 ±4.6	16.3 ±11.6	0.003*	18.6 ±6.9	5.1 ±9.8	0.072
CD3+CD4+CD8−	18.7 ±4	8.5 ±3.5	10.2 ±8.7	0.002*	11.3 ±4.3	2.8 ±6.5	0.128
CD3+CD4+CD8+	0.6 ±0.5	0.1 ±0.1	0.4 ±0.5	0.099	0.3 ±0.3	0.2 ±0.3	0.033*
CD3+CD4−CD8+	9.7 ±3.8	3.9 ±1.3	5.9 ±4.9	0.025*	5.6 ±2.4	1.8 ±3.2	0.062
CD3+CD4−CD8−	0.9 ±0.5	1.0 ±1.1	0.1 ±2.2	0.724	1.1 ±0.9	0.1 ±1.5	0.735
CD3+CD56+	0.6 ±0.3	0.4 ±0.4	0.2 ±0.8	0.215	0.6 ±0.6	0.2 ±0.8	0.434
CD19+	4.2 ±1.3	2.0 ±1.2	2.3 ±2.9	0.014*	2.7 ±1.6	0.7 ±1.8	0.173
Basophils	0.6 ±0.3	0.7 ±0.4	−0.06 ±0.9	0.748	0.8 ±0.5	0.1 ±0.5	0.736
Monocytes CD14+CD16−	5.3 ±0.7	5.4 ±1.3	−0.1 ±3.0	0.803	5.9 ±2.3	0.5 ±2.6	0.466
Monocytes CD14+CD16+	0.9 ±0.4	0.7 ±0.3	0.2 ±0.8	0.477	1.6 ±1.5	0.9 ±1.5	0.090
CD141 mDC	0.01 ±0	0.01 ±0.01	0 ±0.01	0.670	0.01 ±0.01	0 ±0.1	0.135
CD1c mDC	0.2 ±0.04	0.2 ±0.1	−0.04 ±0.2	0.244	0.2 ±0.1	0.1 ±0.1	0.127
NK CD56+CD16−	0.2 ±0.1	0.1 ±0.1	0.1 ±0.2	0.123	0.1 ±0.1	0.2 ±0.1	0.575
NK CD56+CD16+	4.6 ±1.8	1.4 ±0.9	3.2 ±2.2	0.014*	2.1 ±1.0	0.7 ±1.4	0.064
pDC	0.2 ±0.1	0.1 ±0.1	0.1 ±0.1	0.039*	0.1 ±0.1	0	0.278

¹independent t-test,

²paired t-test,

^*p ≤ 0.05